SCHEMBL6898751

SCHEMBL6898751

CCCCc1ccc(CC#N)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.50
TSHR P16473 1/20 0.50
CA2 P00918 2/20 0.48
CA1 P00915 1/20 0.48
ALDH1A1 P00352 4/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
ESR1 P03372 2/20 0.45
ADRA2A P08913 2/20 0.45
ADORA3 P0DMS8 2/20 0.45
TACR2 P21452 2/20 0.45
SLC6A2 P23975 2/20 0.45
SLC6A4 P31645 2/20 0.45
SLC6A3 Q01959 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
SHBG P04278 1/20 0.45
TP53 P04637 1/20 0.45
CYP3A4 P08684 1/20 0.45
HSPD1 P10809 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10896806 0.94 HSD17B10 (0.59) HSD17B10TSHRCA2CA1ALDH1A1
SCHEMBL846409 0.94 HSD17B10 (0.58) HSD17B10TSHRCA2ALDH1A1ESR1
SCHEMBL10897775 0.88 HSD17B10 (0.67) HSD17B10TSHRALDH1A1HPGDSMN1; SMN2
SCHEMBL9552905 0.88 HSD17B10 (0.67) HSD17B10TSHRALDH1A1HPGDSMN1; SMN2
SCHEMBL10900932 0.87 HSD17B10 (0.70) HSD17B10TSHRALDH1A1HPGDSMN1; SMN2
SCHEMBL10898694 0.87 HSD17B10 (0.70) HSD17B10TSHRALDH1A1HPGDSMN1; SMN2
SCHEMBL10898705 0.87 HSD17B10 (0.70) HSD17B10TSHRALDH1A1HPGDSMN1; SMN2
SCHEMBL31258 0.86 LPL (0.45) HSD17B10TSHRCA2ALDH1A1KDM4E
SCHEMBL31324214 0.83 HSD17B10 (0.50) HSD17B10TSHRCA2CA1ALDH1A1
SCHEMBL10896822 0.81 TSHR (0.49) HSD17B10TSHRCA2ALDH1A1RARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2004315513-A METHOD FOR PRODUCING ACRYLONITRILE COMPOUND NISSAN CHEM IND LTD 2004-11-11 JP claimed
US-12617762-B2 Carboxy derivatives with antiinflamatory properties SITRYX THERAPEUTICS LIMITED (GB) 2026-05-05 US disclosed
EP-4081511-B3 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2026-03-04 EP disclosed
US-12459908-B2 Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties SITRYX THERAPEUTICS LIMITED (GB) 2025-11-04 US disclosed
US-20240335451-A1 ACRYLAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS SITRYX THERAPEUTICS LIMITED (GB) 2024-10-10 US disclosed
EP-4442319-A2 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2024-10-09 EP disclosed
EP-4081511-B1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2024-07-31 EP disclosed
EP-4359390-A1 ACRYLAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS Sitryx Therapeutics Limited (GB) 2024-05-01 EP disclosed
US-20240018111-A1 ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2024-01-18 US disclosed
US-20240018111-A1 ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2024-01-18 US disclosed
EP-4192821-A1 ALPHA,BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2023-06-14 EP disclosed
WO-2022269251-A1 ACRYLAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS SITRYX THERAPEUTICS LIMITED (GB) 2022-12-29 WO disclosed
EP-4081511-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2022-11-02 EP disclosed
CN-115066418-A Carboxy derivatives with anti-inflammatory properties 西特瑞治疗有限公司 2022-09-16 CN disclosed
US-20220017507-A1 PI-Kinase Inhibitors with Anti-Infective Activity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-01-20 US disclosed
WO-2021130492-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2021-07-01 WO disclosed
WO-2021130492-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2021-07-01 WO disclosed
CN-106336891-B A method of for reducing the composition of hydrocarbon ils tenor and its application and a kind of reduction hydrocarbon ils tenor 中国石油化工股份有限公司 2018-08-28 CN disclosed
CN-106336891-A Composition used for reducing hydrocarbon oil metal content and its application and method for reducing hydrocarbon oil metal content 中国石油化工股份有限公司 2017-01-18 CN disclosed
JP-2004315513-A METHOD FOR PRODUCING ACRYLONITRILE COMPOUND NISSAN CHEM IND LTD 2004-11-11 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459908-B2 Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties PTGS1, PTGER1, PTGES2 HSD17B10 483/4885TSHR 3299/4885CA2 2741/4885
US-20240335451-A1 ACRYLAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS TNF, HLA-DRB1, GSTK1 HSD17B10 2393/4885TSHR 2546/4885CA2 3387/4885
US-12617762-B2 Carboxy derivatives with antiinflamatory properties CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 HSD17B10 1051/4885TSHR 3443/4885CA2 902/4885
US-20220017507-A1 PI-Kinase Inhibitors with Anti-Infective Activity PIP4K2A, PIP5K1A, PIP4K2C HSD17B10 4546/4885TSHR 4270/4885CA2 2778/4885
US-20240018111-A1 ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES PTGS1, PTGER1, PTGES2 HSD17B10 483/4885TSHR 3299/4885CA2 2741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.